EN PT


0126/2021 - The Butantan Institute and the Brazilian AntiCOVID Vaccine
O Instituto Butantan e a Vacina Brasileira AntiCOVID

Author:

• Reinaldo Guimarães - Guimarães, R. - <reinaldo.guimaraes47@gmail.com>
ORCID: https://orcid.org/0000-0002-0138-9594


Abstract:

The text explores the theme of Brazilian sufficiency in vaccines. It presents the ways practiced in the two most important Brazilian institutions in the development and production of vaccines – the Butantan Institute and the Institute of Technology in Immunobiologicals (Bio-Manguinhos). These paths are the pure and simple purchase, the purchase of the product with technology transfer commitment, partnerships that include the fulfillment of phase 3 trials by the buyer, the new path announced by Instituto Butantan in which the partnership includes for the realization of trials in phases 1 and 2 and, finally, the invention, development and local vaccine production. The latter is only mentioned as a possibility currently not achieved. Finally, the text presents data on the chances of success in vaccine development.

Keywords:

Vaccines; Technological Development; Industry; Public Health

Content:

Access Issue in Scielo

Other languages:







How to

Cite

Guimarães, R.. The Butantan Institute and the Brazilian AntiCOVID Vaccine. Cien Saude Colet [periódico na internet] (2021/Apr). [Citado em 10/05/2025]. Está disponível em: http://cienciaesaudecoletiva.com.br/en/articles/the-butantan-institute-and-the-brazilian-anticovid-vaccine/18025



Execution



Sponsors